null

null

null

null

Minimal debt; Wave is primarily equity-financed with cash runway from equity raises; low leverage ratio near 0x EBITDA

Minimal direct debt exposure; rising rates modestly reduce NPV of future cash flows but don't materially impact operations

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Japan (oligonucleotide synthesis reagents) and China (raw phosphoramidite chemical precursors) are top two chokepoints

Revenue primarily USD-denominated via partner agreements; limited direct exposure to JPY, EUR, or SGD devaluation risk

Operations in US, Singapore, Japan; JPY and SGD exposure modest; most collaboration revenue settled in USD, limiting FX translation risk

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on specialized oligonucleotide synthesis suppliers; few qualified GMP-grade vendors globally, creating non-substitutable single-source risk

Cloud infrastructure not operationally critical; Wave's core is wet-lab biotech R&D; AWS termination would cause IT disruption, not pipeline loss

Hybrid biopharma: internal R&D platform monetized via partnerships and licensing; not cloud-native business model

Low cloud API coupling risk; Wave uses standard bioinformatics tools; switching cloud providers feasible within 60–90 days with moderate cost

Revenue model is milestone/royalty licensing from pharma partners, not securities-like; Howey Test risk is negligible

Very High

Limited consumer data exposure; clinical trial data governed by ICH/GCP; GDPR/CCPA risk low given no direct patient data commercialization

Low antitrust risk; niche RNA editing platform in competitive biotech space; no dominant market position or pricing control

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based collaboration revenue; no recurring subscription revenue; highly lumpy milestone recognition

Upfront license fees, R&D reimbursements, and contingent milestones from pharma partners (e.g., Takeda, GSK previously)

Milestone pricing set via negotiated partnership agreements; limited pricing power stress vulnerability but milestone delays create revenue gaps

Moderate; proprietary stereopure oligonucleotide platform provides differentiation but partners hold significant negotiating leverage

Collaboration gross margins potentially 60–80%; but R&D spend dominates, producing deeply negative operating margins currently

No free-rider problem; proprietary platform is IP-protected; partner churn risk exists if clinical programs fail

Revenue growth is sublinear to headcount once platform matures; current stage is headcount-heavy R&D; scale improves leverage over time

Marginal cost of additional partnership revenue is low once platform validated; key cost is clinical execution, not proportional headcount

Not applicable; Wave is not a franchise business

At 10x scale, CAC economics improve significantly; pharma business development is relationship-driven with high LTV per partner

No meaningful network effect; platform value is IP and data-driven, not network-dependent; durability relies on clinical proof-of-concept

-32.0% Return on Assets (Negative equity)

Moderate resilience; pharma partners have long R&D cycles but may cut early-stage deals in severe downturns; not consumer-facing

Large pharmaceutical and biotechnology companies seeking RNA-targeting therapeutic partnerships

Government/NIH grant funding as secondary non-dilutive capital source; academic collaborators for platform validation

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.7% CapEx / Revenue (Low-CapEx Asset-Light)

0001631574

WVE